“Experts” are actually arguing that patients should have increased access to drugs not yet tested and that this should be done on compassionate grounds. This article, by the way, came out a few days before the FDA decided to restrict Avandia, a drug that HAD ALREADY BEEN APPROVED because it increased the likelihood of heart attack

The NYT is live blogging the debate on whether to pull the diabetes drug Avandia from the shelves. A federal advisory panel is hearing testimoney about how safe it is, how safe it isn’t, what the problems may be… when did science becaome so much about opinion? When did clinical trials have so much wiggle room? Makes one wonder. But, enough, now to the blogging …